Comparison of histopathological grading and staging of breast cancer with p53-positive and transforming growth factor-beta receptor 2-negative immunohistochemical marker expression cases

2020 ◽  
Vol 6 (2) ◽  
pp. 30
Author(s):  
Anindya Adhikari ◽  
PalashKumar Mandal ◽  
Subir Biswas ◽  
Amita Giri ◽  
Arnab Gupta ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Transforming Growth Factor Beta ◽  
Transforming Growth Factor ◽  
Beta Receptor ◽  
Immunohistochemical Marker ◽  
Growth Factor Beta ◽  
Marker Expression ◽  
Histopathological Grading

scholarly journals Differential expression of transforming growth factor beta receptor 2 in cancers of the breast.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Differential Expression ◽  
Transforming Growth Factor Beta ◽  
Transforming Growth Factor ◽  
Normal Breast ◽  
Differentially Expressed ◽  
Primary Tumors ◽  
Beta Receptor ◽  
Growth Factor Beta

Breast cancer affects women at relatively high frequency (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding transforming growth factor beta receptor 2, TGFBR2, when comparing primary tumors of the breast to the tissue of origin, the normal breast. TGFBR2 mRNA was present at significantly lower quantities in tumors of the breast as compared to normal breast tissue. Analysis of human survival data revealed that expression of TGFBR2 in primary tumors of the breast was correlated with recurrence-free survival in patients with HER2+ subtype cancers, demonstrating a relationship between primary tumor expression of a differentially expressed gene and patient survival outcomes influenced by molecular subtype. TGFBR2 may be of relevance to initiation, maintenance or progression of cancers of the female breast.

Osteoinductive effect of soluble transforming growth factor beta receptor 3 on human osteoblast lineage

2021 ◽  
Author(s):  
Angelica Mastandrea Amanso ◽  
Archana Kamalakar ◽  
Sara Bitarafan ◽  
Shelly Abramowicz ◽  
Hicham Drissi ◽  
...  
Keyword(s):  
Growth Factor ◽  
Transforming Growth Factor Beta ◽  
Transforming Growth Factor ◽  
Human Osteoblast ◽  
Beta Receptor ◽  
Growth Factor Beta ◽  
Osteoblast Lineage

Structure and Polymorphism Analysis of Transforming Growth Factor Beta Receptor 1 (TGFBR1) in Pigs

2005 ◽  
Vol 43 (9-10) ◽  
pp. 491-500 ◽  
Author(s):  
Shin-ichi Shimanuki ◽  
Ayumi Mikawa ◽  
Yuko Miyake ◽  
Noriyuki Hamasima ◽  
Satoshi Mikawa ◽  
...  
Keyword(s):  
Growth Factor ◽  
Transforming Growth Factor Beta ◽  
Transforming Growth Factor ◽  
Polymorphism Analysis ◽  
Beta Receptor ◽  
Growth Factor Beta

Abstract 897: Association between transforming growth factor beta 1 and progression-free survival in breast cancer

2021 ◽  
Author(s):  
George Ruochen Yang ◽  
Cristiane Takita ◽  
Jean L. Wright ◽  
Isildinha M. Reis ◽  
Eunkyung Lee ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Transforming Growth Factor Beta ◽  
Transforming Growth Factor ◽  
Progression Free Survival ◽  
Free Survival ◽  
Growth Factor Beta

Transforming Growth Factor Beta 1 Serum Levels in Patients with Preinvasive and Invasive Lesions of the Breast

2004 ◽  
Vol 19 (3) ◽  
pp. 236-239 ◽  
Author(s):  
A. Lebrecht ◽  
C. Grimm ◽  
G. Euller ◽  
E. Ludwig ◽  
E. Ulbrich ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Transforming Growth Factor Beta ◽  
Transforming Growth Factor ◽  
Serum Levels ◽  
Breast Carcinogenesis ◽  
Receptor Status ◽  
Healthy Women ◽  
Growth Factor Beta ◽  
Tgf Β1

Transforming growth factor beta (TGF-β)1 is thought to be involved in breast carcinogenesis. TGF-β1 acts in an antiproliferative manner in the early stages of breast carcinogenesis, but promotes tumor progression and metastases in the advanced stages of the disease. No data have been published on serum TGF-β1 in breast cancer. We investigated TGF-β1 serum levels in patients with breast cancer (n=135), ductal carcinoma in situ (DCIS) I to III (n=67) or fibroadenoma (n=35), and in healthy women (n=40) to determine its value as a differentiation marker between malignant, pre-invasive and benign diseases and as a predictive marker for metastatic spread. Median (range) TGF-β1 serum levels in patients with breast cancer, DCIS I-III or benign breast lesions and in healthy women were 48.8 (18–82.4) pg/mL, 45.3 (26.9–58.3) pg/mL, 47.2 (17.2–80.5) pg/mL and 51.6 (30.9–65.1) pg/mL, respectively (p=0.2). In breast cancer patients TGF-β1 serum levels showed no statistically significant correlation with tumor stage, lymph node involvement, histological grade, estrogen receptor status and progesterone receptor status. Our data fail to indicate any correlation between serum TGF-β1 levels and clinicopathological parameters of breast diseases. Serum TGF-β1 levels do not provide clinical information in addition to established tumor markers.

Sign in / Sign up

Export Citation Format

Share Document